A Phase 2/3 interventional study of L-Carnitine 500Mg thrice daily and 1g L-Carnitine IV three times a week in Hemodialysis Complication, sponsored by Bahria University. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Bahria University · Phase 2/3, Interventional, and Supportive care
OBJECTIVES
.ABSTRACT INTRODUCTION Dialysis therapy can cause a decrease in both free carnitine and plasma acyl carnitines after only six months of dialysis treatment. A positive correlation between AC/FC ratio and months on HD therapy has been reported. We investigate in this study the role of oral L-carnitine supplementation on anemia, blood pressure, cardiac dysfunction and muscle cramps in hemodialysis patients.
OBJECTIVES
STUDY DESIGN AND SETTING: It will be a case-control study, which will be conducted in the Department of Biochemistry, University of Karachi in collaboration with Nephrology ward of JPMC, Karachi in a period of one year after approval of synopsis.
METHOD: Total 120 subjects will be included in this study which will be divided into two groups. Group A will comprise of 60 subjects of Chronic renal failure who will be the control group. Group B will comprise of 60 subjects who will be on hemodialysis for more than 1 year. Blood samples will be taken after informed consent. Group B subjects will be given L-Carnitine supplementation for five months under strict monitoring. Physical, biochemical and clinical parameters of group B subjects will be compared before and after supplementation.
RESULTS: Data will be analyzed using SPSS version 21. Results will be shared after completion of research.
CONCLUSION: conclusion will be shared after completion of research.
2,085 studies on the registry are indexed under Kidney Failure, Chronic; 260 are open to participants now.
This study's enrollment of 83 is above the median of 55 across 1,557 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →Bahria University is the lead sponsor of 35 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: • Individuals of either sex (male and female).
Exclusion Criteria:
Individuals with any other chronic ailment, such as cancer or tuberculosis.
L-Carnitine 500mg thrice daily 1g L-Carnitine IV three times a week
Drug: L-Carnitine 500Mg thrice daily · Drug: 1g L-Carnitine IV three times a week
no intervention given
L-Carnitine 500mg oral thrice daily
1g IV L-Carnitine three times a week
L-Carnitine levels in hemodialysis
plasma carnitine will be detected before and after giving intervention (unit μmol/L)
Time frame: 5 months
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bahria University